Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab

References

• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23. doi:10.1056/NEJMoa1003466. PMID:20525992
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of long-term survival data from phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889-94. doi:10.1200/JCO.2014.56.2736. PMID:25667295
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26. doi:10.1056/NEJMoa1104621. PMID:21639810
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522-30. doi:10.1016/S1470-2045(15)70122-1. PMID:25840693
   PubMed Web of Science ®Google Scholar
• Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827-37. doi:10.1158/2159-8290.CD-15-1545. PMID:27301722
   PubMed Web of Science ®Google Scholar
• Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology. 2013;2:e26615. doi:10.4161/onci.26615. PMID:24251082
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50. doi:10.1186/s40425-016-0152-y. PMID:27532025
   PubMed Web of Science ®Google Scholar
• Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11. doi:10.1186/s40425-015-0057-1. PMID:25901283
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-55. doi:10.1056/NEJMoa1609214. PMID:27806233
   PubMed Web of Science ®Google Scholar
• Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: A case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4. doi:10.1186/s40425-015-0048-2. PMID:25705383
   PubMed Web of Science ®Google Scholar
• Cheng F, Loscalzo J. Autoimmune cardiotoxicity of cancer immunotherapy. Trends Immunol. 2017;38:77-8. doi:10.1016/j.it.2016.11.007. PMID:27919707
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol. 2017;29:136-44. doi:10.1097/CCO.0000000000000358. PMID:28059853
   PubMed Web of Science ®Google Scholar
• Kandolin R, Lehtonen J, Salmenkivi K, Raisanen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15-22. doi:10.1161/CIRCHEARTFAILURE.112.969261. PMID:23149495
   PubMed Web of Science ®Google Scholar
• Xu J, Brooks EG. Giant cell myocarditis: A brief review. Arch Pathol Lab Med. 2016;140:1429-34. doi:10.5858/arpa.2016-0068-RS. PMID:27922771
   PubMed Web of Science ®Google Scholar
• Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, Mertz KD. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer. 2016;4:13. doi:10.1186/s40425-016-0117-1. PMID:26981243
   PubMed Web of Science ®Google Scholar
• Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res. 2016;26:319-20. doi:10.1097/CMR.0000000000000251. PMID:27110676
   PubMed Web of Science ®Google Scholar
• Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis–natural history and treatment. Multicenter giant cell myocarditis study group investigators. N Engl J Med. 1997;336:1860-6. doi:10.1056/NEJM199706263362603. PMID:9197214
   PubMed Web of Science ®Google Scholar
• Yuan Z, Shioji K, Kishimoto C. Immunohistological analyses of myocardial infiltrating cells in various animal models of myocarditis. Exp Clin Cardiol. 2003;8:13-6. PMID:19644581
   PubMedGoogle Scholar
• Fousteri G, Dave A, Morin B, Omid S, Croft M, von Herrath MG. Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimmun. 2011;36:210-20. doi:10.1016/j.jaut.2011.01.006. PMID:21333491
   PubMed Web of Science ®Google Scholar
• Hirota Y, Osuga Y, Koga K, Yoshino O, Hirata T, Morimoto C, Harada M, Takemura Y, Nose E, Yano T, et al. The expression and possible roles of chemokine CXCL11 and its receptor CXCR3 in the human endometrium. J Immunol. 2006;177:8813-21. doi:10.4049/jimmunol.177.12.8813. PMID:17142784
   PubMed Web of Science ®Google Scholar
• Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. npj Genomic Med. 2017;2:10. doi:10.1038/s41525-017-0013-8
   PubMedGoogle Scholar